Navigation Links
Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
Date:9/13/2007

LOS ANGELES, Sept. 13 /PRNewswire-FirstCall/ --- Response Genetics, Inc. (Nasdaq: RGDX), today announced its President and CEO, Kathleen Danenberg, will provide a business overview at the following investor conferences:

-- ThinkEquity Partners' 5th Annual Growth Conference at the St. Regis Hotel in San Francisco on Tuesday, September 18th at 8:30 a.m. PDT.

-- Maxim Group's 1st Annual Growth Conference at the Grand Hyatt Hotel in New York City on Thursday, September 20th at 3:30 p.m. EDT.

Both presentations will be made available by webcast and can be accessed on the Media page of Response Genetics' website at http://www.responsegenetics.com.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit htt
'/>"/>

SOURCE Response Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. Speaker announces business members of IT Task Force
9. Doyle announces technology tax credits for Berbee
10. Doyle announces new energy, global warming policies
11. Doyle announces $80M renewable energy strategy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...v. 24 Sigma-Aldrich Corp... NASDAQ OMX conference on Tuesday, December 1st at... parties may listen via live audio broadcast over ...g m a a ldrich.com/ . Users can click the "W...Sigma-Aldrich: Sigma-Aldrich is a leading Life S...
(Date:11/24/2009)...alif., Nov. 24 NeurogesX...ny focused on developing and commercializing novel...nthony DiTonno, President and Chief Executive Offi...per Jaffray Health Care Conference, to be held Dec...w York, New York. ,, Mr. DiTonno and Stephen G...
(Date:11/24/2009)...ficacy endpoint has been met for patients with adv...,, QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ ... (the "Company"), a global biopharmaceutical compa...y announced positive efficacy data from a Phase 2 ...e, AEZS-108 (formerly AN-152), in patients with ad...
(Date:11/24/2009)...Calif., Nov. 24 Genomic ... Randy Scott, Genomic Health,s Executive Chairman,...lth Care Conference in New York City on Tuesday, D... the live and subsequently archived webcast of the...n of Genomic Health,s website at http://investor....
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
..., , , , , , , Multip... , , Transformation Proto...01 , , , , , , ,... Organism , Neurospora crassa, ... Filamentous fungus, conidia, , ...
..., , , , , , , Multip..., , , , , , ...o. 4308 915.520 12/2001 , , , ..., , Microorganism , ... , Cell type , Bacteria, ...
..., , , , , , , Multip... , , Transfection Protoco... , , , , , , ,... Cell line , HeLa, human cervix epithel...Transfection with , Plasmid pEGFP-N1 (i...
Other Biology Technology:Neurospora crassa 2Listeria monocytogenes 2HeLa 2
(Date:11/26/2009)...ts have at last worked out a way of using recordin...ird populations. This is the first time sound reco...d into accurate estimates of bird species, populat...ritish Ecological Society,s Journal of Applied Ec...ead to a major advance in our ability to monitor w...
(Date:11/26/2009)...thicillin-resistant Staphylococcus Aureus ) and o...on as low-temperature plasma prototype devices hav...failing bactericidal cocktails. , Two prototype ...infection of healthy skin (e.g. hands and feet) in...se a lethal threat; and another to shoot bacteria-...
(Date:11/25/2009)...mber 11, firefighters, police officers and ambulan... World Trade Center complex. They battled to save ...or survivors, tackled fires and evacuated as many ... estimated 17,000 people. And making their jobs ev...frightened workers and their relatives jammed mobi...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 1Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 2Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 3Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 4Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 5Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 6Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 1Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 2Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 3Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 4Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 5Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 6Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 7Reportlinker Adds The World Market for Gastrointestinal Endoscopy Equipment Report 57996 8Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 1Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 2Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 3Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 4Innovative Medical Technology Companies From Around the World Selected to Present Profiles to Industry Leaders 26 Financiers at AdvaMed 2009 57994 5
...e believed to contain a toxic antimicrobial chemic...crutinized despite large scale,production and usag...sis conducted by researchers at the Johns Hopkins ...riclocarban, has been widely used for,decades in h...was,monitored for or detected in the environment. ...
...ease have surprised scientists with their ability ...brain plaques are removed.,Researchers at Washingt...cted mice with an antibody for a key component of ...n areas of the brain where,antibodies cleared plaq...nerve cell branches rapidly disappeared. , "These,...
...ease have surprised scientists with their ability ...brain plaques are removed.,Researchers at Washingt...cted mice with an antibody for a key component of ...n areas of the brain where,antibodies cleared plaq...nerve cell branches rapidly disappeared. , "These,...
Other Biology News:Anti-bacterial additive widespread in U.S. waterways 2Key molecule in plant photo-protection identified 2Key molecule in plant photo-protection identified 3Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 2Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 3
Rabbit Anti-Human ADAM-12 (Meltrin alpha), carboxy terminal end Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-hnRNP F / H Monoclonal Antibody, Unconjugated, Clone 1G11 from Novus Biologicals
Rabbit Anti-MKK6, phospho (Ser207) Polyclonal Antibody, Unconjugated from Abcam
Custom Oligo Assay Single Locus 1920 samples from Illumina
Biology Products: